Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Solid Tumor 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 18fludarabine phosphate 16Rituximab 16Etoposide 16Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14fludarabine 11Whole-Body Irradiation 11Nivolumab 11Mycophenolic Acid 11Bendamustine Hydrochloride 11Tacrolimus 10Melphalan 10Filgrastim 9Gemcitabine 8Carboplatin 8Ifosfamide 7Cytarabine 7Cyclosporine 7Busulfan 7pembrolizumab 6Lenalidomide 6Doxorubicin 6Prednisone 5Everolimus 5Antilymphocyte Serum 5Alemtuzumab 5Vinblastine 4Methotrexate 4Mesna 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hodgkin Disease × SHR-1701 × Clear all
NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡